Back

Patient receptiveness to statin therapy is higher when presented with lifetime risk rather than 10-year risk of cardiovascular disease: insights from the PALM registry

30 August 2016 (15:51 - 16:00)
Organised by:
Congress Presentation Part of: Cardiovascular risk scores: novel tunes in a familiar music Risk scores ESC Premium Access ESC Congress 2016

About the speaker

Photo
Associate Professor Ann Marie Navar

University of Texas Southwestern Medical Center, Dallas (United States of America)

5 More presentations in this session

Presentation thumbnail
How user friendly is CHA2DS2Vasc score?
Doctor K. Golubic (Zagreb, HR)
Abstract Slides
Presentation thumbnail
CHADS2 and CHA2DS2VASc predict short and long-term mortality in patients with cardiovascular diseases admitted to the hospital
Professor G. Weisz (Jerusalem, IL)
Abstract Slides
Presentation thumbnail
Reclassification of the Intermediate group classified according to HEARTSCORE taking in consideration individual genetic predisposition to Coronary artery disease.
Doctor A. Pereira (Funchal, PT)
Abstract
Presentation thumbnail
Identifying patients with vascular disease at Very High Risk (VHR) for recurrent events according to the ACC/AHA and ESC guideline criteria.
Ms M. van den Berg (Utrecht, NL)
Abstract
Presentation thumbnail
Accuracy of PCE, SCORE and QRISK2 scores in predicting cardiovascular disease in Estonia, a high risk European country
Doctor A. Elken (Tallinn, EE)
Abstract Slides

Access the full session

Session thumbnail
Cardiovascular risk scores: novel tunes in a familiar music

The Event

Event poster

ESC Congress 2016

30 August 2016 15:51 CET
You may be interested in
thumbnail
Congress Presentation
Optimal medical therapy for primary prevention
27 August 2023
thumbnail
Congress Presentation
Effects of combining coronary calcium score with treatment on plaque progression in familial coronary artery disease: CAUGHT-CAD RCT
1 September 2025
thumbnail
Congress Presentation
Predicted lifetime therapy benefit guided treatment effectively reduces residual cardiovascular risk in patients with symptomatic atherosclerotic disease
29 August 2020
thumbnail
Congress Presentation
NATURE-LEGACY: Long term legacy benefit of Lowering LDL and SBP
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources